Display options
Cite
Balbach L, Wallaschofski H, Völzke H, et al. Serum prolactin concentrations as risk factor of metabolic syndrome or type 2 diabetes?. BMC Endocr Disord. 2013;13:12doi: 10.1186/1472-6823-13-12.
Balbach, L., Wallaschofski, H., Völzke, H., Nauck, M., Dörr, M., & Haring, R. (2013). Serum prolactin concentrations as risk factor of metabolic syndrome or type 2 diabetes?. BMC endocrine disorders, 1312. https://doi.org/10.1186/1472-6823-13-12
Balbach, Lisa, et al. "Serum prolactin concentrations as risk factor of metabolic syndrome or type 2 diabetes?." BMC endocrine disorders vol. 13 (2013): 12. doi: https://doi.org/10.1186/1472-6823-13-12
Balbach L, Wallaschofski H, Völzke H, Nauck M, Dörr M, Haring R. Serum prolactin concentrations as risk factor of metabolic syndrome or type 2 diabetes?. BMC Endocr Disord. 2013 Mar 21;13:12. doi: 10.1186/1472-6823-13-12. PMID: 23517652; PMCID: PMC3614874.
Copy Download .nbib Format: NLM
Share it on

BMC Endocr Disord. 2013 Mar 21;13:12. doi: 10.1186/1472-6823-13-12.

Serum prolactin concentrations as risk factor of metabolic syndrome or type 2 diabetes?.

BMC endocrine disorders

Lisa Balbach, Henri Wallaschofski, Henry Völzke, Matthias Nauck, Marcus Dörr, Robin Haring

Affiliations

  1. Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Ferdinand-Sauerbruch-Straße, Greifswald, 17475, Germany. [email protected].

PMID: 23517652 PMCID: PMC3614874 DOI: 10.1186/1472-6823-13-12

Abstract

BACKGROUND: To investigate potential associations of serum prolactin concentration (PRL) with metabolic syndrome (MetS) and type 2 diabetes mellitus (T2DM), previously observed in small and selected study samples, in a large population-based cohort.

METHODS: Data from 3,993 individuals (2,027 women) aged 20-79 years from the population-based Study of Health of Pomerania (SHIP) were used to analyse cross-sectional and longitudinal associations of PRL with MetS and T2DM risk in age- and multivariable-adjusted Poisson regression models. PRL were log-transformed and modelled as continuous (per standard deviation (SD) increase) and categorical predictor (sex-specific quartiles) variable, separately for men and woman.

RESULTS: Cross-sectional analyses showed an inverse association between low PRL concentrations and prevalent T2DM risk in men and women after multivariable-adjustment (men: Q1 vs. Q4: relative risk (RR), 1.55; 95% confidence interval (CI), 1.13 - 2.14; women: Q1 vs. Q4: RR, 1.70; 95% CI, 1.10 - 2.62). Likewise, higher PRL concentrations were associated with significantly lower T2DM risk (RR per SD increase in log-PRL: 0.83; 95% CI, 0.72 - 0.95 in men, and 0.84; 95% CI, 0.71 - 0.98 in women, respectively). An inverse association between PRL and MetS risk was not retained after multivariable adjustment. Longitudinal analyses yielded no association of PRL with incident MetS or T2DM.

CONCLUSION: The present study is the first large population-based study reporting a cross-sectional inverse association between PRL and prevalent T2DM in both genders. But the absent longitudinal associations do not support a causal role of PRL as a risk factor of incident MetS or T2DM.

References

  1. Autoimmun Rev. 2009 Sep;9(1):23-7 - PubMed
  2. Eur J Cardiovasc Prev Rehabil. 2011 Feb;18(1):86-96 - PubMed
  3. Eur Heart J. 2014 May;35(18):1215-21 - PubMed
  4. Exp Clin Endocrinol Diabetes. 2010 Nov;118(10):685-91 - PubMed
  5. Endocr Rev. 2010 Oct;31(5):663-79 - PubMed
  6. Trends Endocrinol Metab. 2006 Apr;17(3):110-6 - PubMed
  7. Am J Public Health. 2005;95 Suppl 1:S144-50 - PubMed
  8. Clin Chem. 1995 Dec;41(12 Pt 1):1761-7 - PubMed
  9. Transplantation. 2010 Jun 15;89(11):1328-35 - PubMed
  10. Diabetologia. 2011 Jun;54(6):1388-97 - PubMed
  11. Int J Epidemiol. 2011 Apr;40(2):294-307 - PubMed
  12. J Clin Endocrinol Metab. 2008 Oct;93(10):3671-89 - PubMed
  13. Endocrinology. 2004 Sep;145(9):4162-75 - PubMed
  14. Annu Rev Public Health. 2007;28:95-111 - PubMed
  15. Int J Androl. 2011 Jun;34(3):217-24 - PubMed
  16. Pituitary. 2008;11(2):209-18 - PubMed
  17. J Clin Endocrinol Metab. 2006 Feb;91(2):718-21 - PubMed
  18. Acta Diabetol. 2009 Jun;46(2):85-95 - PubMed
  19. Transplant Proc. 2008 Mar;40(2):382-3 - PubMed
  20. Diabetes Obes Metab. 2003 Mar;5(2):106-12 - PubMed
  21. Diabetes Obes Metab. 2007 Jul;9(4):464-76 - PubMed
  22. Circulation. 2009 Oct 20;120(16):1640-5 - PubMed
  23. Obes Surg. 2009 Aug;19(8):1159-62 - PubMed
  24. Biol Psychiatry. 1994 Feb 1;35(3):151-63 - PubMed
  25. Life Sci. 2002 Jul 19;71(9):979-92 - PubMed
  26. Diabetes. 2009 Sep;58(9):2027-31 - PubMed
  27. Aging Male. 2011 Sep;14(3):176-82 - PubMed
  28. Postgrad Med. 2012 Jan;124(1):21-30 - PubMed
  29. Obesity (Silver Spring). 2008 Aug;16(8):1831-7 - PubMed
  30. Pituitary. 2011 Sep;14(3):199-207 - PubMed
  31. Atherosclerosis. 2012 Apr;221(2):570-6 - PubMed
  32. Endocrinology. 2002 Apr;143(4):1378-85 - PubMed
  33. Eur J Endocrinol. 2011 May;164(5):751-8 - PubMed
  34. J Clin Endocrinol Metab. 1998 Mar;83(3):761-4 - PubMed
  35. Clin Endocrinol (Oxf). 2006 Apr;64(4):366-70 - PubMed
  36. Am J Psychiatry. 2003 Feb;160(2):284-9 - PubMed
  37. Eur J Endocrinol. 2010 Oct;163(4):625-30 - PubMed
  38. J Clin Endocrinol Metab. 2012 Feb;97(2):408-15 - PubMed
  39. Obesity (Silver Spring). 2011 Apr;19(4):800-5 - PubMed
  40. J Cell Physiol. 2012 Aug;227(8):3001-6 - PubMed
  41. J Sex Med. 2009 May;6(5):1457-66 - PubMed
  42. J Clin Endocrinol Metab. 2004 Jan;89(1):266-71 - PubMed
  43. Clin Endocrinol (Oxf). 2011 Oct;75(4):561-6 - PubMed
  44. J Clin Epidemiol. 2009 Mar;62(3):252-60 - PubMed
  45. J Endocrinol. 2007 Jun;193(3):367-81 - PubMed

Publication Types